Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07380633CT.gov Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial | — | Active Not Recruiting | — | — | — |
NCT06882876CT.gov JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study | — | Enrolling By Invitation | — | — | — |
NCT06679985CT.gov A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT06201065CT.gov FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | — | Recruiting | — | — | — |
NCT05212922CT.gov A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC | — | Withdrawn | — | — | — |
NCT05757492CT.gov Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05493332CT.gov HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | — | Unknown | — | — | — |
NCT05453383CT.gov Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib | — | Unknown | — | — | — |
NCT05162898CT.gov Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma. | — | Unknown | — | — | — |
NCT05441475CT.gov A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | — | Enrolling By Invitation | — | — | — |
Show 27 more trialsShow fewer
NCT05056337CT.gov Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | — | Unknown | — | — | — |
NCT04709380CT.gov Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | — | Terminated | — | — | — |
NCT04605185CT.gov Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT06323382CT.gov Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06333561CT.gov HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04627363CT.gov HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | — | Unknown | — | — | — |
NCT04723004CT.gov Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | — | Unknown | — | — | — |
NCT04503902CT.gov Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04368078CT.gov Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05240404CT.gov Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma | — | Unknown | — | — | — |
NCT04523493CT.gov Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC | — | Active Not Recruiting | — | — | — |
NCT04374877CT.gov Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04605796CT.gov A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT04069949CT.gov Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus | — | Unknown | — | — | — |
NCT04170179CT.gov Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis | — | Unknown | — | — | — |
NCT04169399CT.gov Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | — | Unknown | — | — | — |
NCT04135690CT.gov HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | — | Unknown | — | — | — |
NCT04926532CT.gov Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04044313CT.gov HAIC Plus Lenvatinib and Toripalimab for Advanced HCC | — | Completed | — | — | — |
NCT03864211CT.gov Thermal Ablation Followed by Immunotherapy for HCC | — | Unknown | — | — | — |
NCT03939975CT.gov Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC | — | Completed | — | — | — |
NCT03966209CT.gov Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | — | Unknown | — | — | — |
NCT03867370CT.gov Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT03919383CT.gov Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | — | Withdrawn | — | — | — |
NCT03859128CT.gov Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection | — | Unknown | — | — | — |
NCT03851939CT.gov The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT04627012CT.gov Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Toripalimab (this asset) | Sun Yat-sen University | P3 | B · 63 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Toripalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 67 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Toripalimab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/toripalimab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →